Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4400597 | 0.84 | TSHR (0.55) | MAPTTSHRNPSR1 | |
| SCHEMBL4405422 | 0.83 | MAPT (0.40) | MAPTTSHRNPSR1 | |
| SCHEMBL4405421 | 0.83 | MAPT (0.40) | MAPTTSHRNPSR1 | |
| SCHEMBL3504566 | 0.82 | MAPT (0.42) | MAPTTSHRNPSR1 | |
| SCHEMBL11747186 | 0.79 | MAPT (0.46) | MAPTTSHRNPSR1 | |
| SCHEMBL28367450 | 0.79 | MAPT (0.46) | MAPTTSHRNPSR1 | |
| SCHEMBL697129 | 0.78 | MAPT (0.44) | MAPTTSHR | |
| SCHEMBL15243937 | 0.76 | TSHR (0.67) | MAPTTSHR | |
| SCHEMBL29362562 | 0.76 | TSHR (0.67) | MAPTTSHR | |
| SCHEMBL35200 | 0.76 | TSHR (0.67) | MAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060142177-A1 | Organic compounds | GIVAUDAN SA (CH) | 2006-06-29 | — | — | US | claimed |
| EP-1633693-A1 | IMPROVEMENTS IN OR RELATED TO ORGANIC COMPOUNDS | Givaudan SA (CH) | 2006-03-15 | — | — | EP | claimed |
| WO-2004108653-A1 | IMPROVEMENTS IN OR RELATED TO ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2004-12-16 | — | — | WO | claimed |
| US-7632964-B2 | 2-methylbutyl 3-methylbutenoate; enhance, improve, or modify the aroma or flavour in food, beverage, pharmaceutical, oral hygiene product or healthcare product | GIVAUDAN S.A. (CH) | 2009-12-15 | — | — | US | disclosed |
| US-20060142177-A1 | Organic compounds | GIVAUDAN SA (CH) | 2006-06-29 | — | — | US | disclosed |
| EP-1633693-A1 | IMPROVEMENTS IN OR RELATED TO ORGANIC COMPOUNDS | Givaudan SA (CH) | 2006-03-15 | — | — | EP | disclosed |
| WO-2004108653-A1 | IMPROVEMENTS IN OR RELATED TO ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142177-A1 | Organic compounds | ELOVL1, ELOVL5, ELOVL3 | MAPT 3572/4885TSHR 2537/4885NPSR1 2626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.